Johnson & Johnson's Second Interim Analysis Of Phase 3 Cartitude-4 Study Of Carvykti Vs. Standard Therapies For Relapsed Or Lenalidomide-Refractory Multiple Myeloma, Show Statistically Significant, Clinically Meaningful Improvement In Overall Survival
Johnson & Johnson's Second Interim Analysis Of Phase 3 Cartitude-4 Study Of Carvykti Vs. Standard Therapies For Relapsed Or Lenalidomide-Refractory Multiple Myeloma, Show Statistically Significant, Clinically Meaningful Improvement In Overall Survival
強生的第二個中期分析Cartitude-4研究報告，顯示Carvykti在復發或Lenalidomide難治性多發性骨髓瘤治療中，與標準治療相比具有統計學意義，臨床上具有顯著的總體生存優勢。
Johnson & Johnson's Second Interim Analysis Of Phase 3 Cartitude-4 Study Of Carvykti Vs. Standard Therapies For Relapsed Or Lenalidomide-Refractory Multiple Myeloma, Show Statistically Significant, Clinically Meaningful Improvement In Overall Survival
強生的第二個中期分析Cartitude-4研究報告，顯示Carvykti在復發或Lenalidomide難治性多發性骨髓瘤治療中，與標準治療相比具有統計學意義，臨床上具有顯著的總體生存優勢。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。